Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

Furkejuvvon:

Bibliográfalaš dieđut
Publikašuvnnas:	NPJ Breast Cancer vol. 10, no. 1 (2024), p. 26
Váldodahkki:	Tarantino, Paolo
Eará dahkkit:	Leone, Julieta, Vallejo, Carlos T., Freedman, Rachel A., Waks, Adrienne G., Martínez-Sáez, Olga, Garrido-Castro, Ana, Lynce, Filipa, Tayob, Nabihah, Lin, Nancy U., Tolaney, Sara M., Leone, Jose P.
Almmustuhtton:	Nature Publishing Group
Fáttát:	Patients Marital status Histology Population-based studies Medical prognosis Mastectomy Cancer therapies Medical research Oncology Tumors Metropolitan areas Chemotherapy Breast cancer Clinical outcomes
Liŋkkat:	Citation/Abstract Full Text - PDF
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

MARC


LEADER	00000nab a2200000uu 4500
001	3032863055
003	UK-CbPIL
022			\|a 2374-4677
024	7		\|a 10.1038/s41523-024-00634-6 \|2 doi
035			\|a 3032863055
045	2		\|b d20240101 \|b d20241231
084			\|a 274865 \|2 nlm
100	1		\|a Tarantino, Paolo \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); University of Milan, Department of Oncology and Onco-Hematology, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
245	1		\|a Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer
260			\|b Nature Publishing Group \|c 2024
513			\|a Journal Article
520	3		\|a To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).
653			\|a Patients
653			\|a Marital status
653			\|a Histology
653			\|a Population-based studies
653			\|a Medical prognosis
653			\|a Mastectomy
653			\|a Cancer therapies
653			\|a Medical research
653			\|a Oncology
653			\|a Tumors
653			\|a Metropolitan areas
653			\|a Chemotherapy
653			\|a Breast cancer
653			\|a Clinical outcomes
700	1		\|a Leone, Julieta \|u Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina (GRID:grid.4708.b)
700	1		\|a Vallejo, Carlos T. \|u Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina (GRID:grid.4708.b)
700	1		\|a Freedman, Rachel A. \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
700	1		\|a Waks, Adrienne G. \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
700	1		\|a Martínez-Sáez, Olga \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Hospital Clinic of Barcelona, Medical Oncology Department, Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Translational Genomics and Targeted Therapeutics in Solid Tumors, Barcelona, Spain (GRID:grid.10403.36) (ISNI:0000000091771775)
700	1		\|a Garrido-Castro, Ana \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
700	1		\|a Lynce, Filipa \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
700	1		\|a Tayob, Nabihah \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
700	1		\|a Lin, Nancy U. \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
700	1		\|a Tolaney, Sara M. \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
700	1		\|a Leone, Jose P. \|u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
773	0		\|t NPJ Breast Cancer \|g vol. 10, no. 1 (2024), p. 26
786	0		\|d ProQuest \|t Health & Medical Collection
856	4	1	\|3 Citation/Abstract \|u https://www.proquest.com/docview/3032863055/abstract/embedded/J7RWLIQ9I3C9JK51?source=fedsrch
856	4	0	\|3 Full Text - PDF \|u https://www.proquest.com/docview/3032863055/fulltextPDF/embedded/J7RWLIQ9I3C9JK51?source=fedsrch